Brief: Alimera Sciences- Phase 4 Paladin Study With Iluvien® Published In Peer-Reviewed Journal Ophthalmology
23/02/2022 14:14
Feb 23 (Reuters) - Alimera Sciences Inc ALIM.O :
* PHASE 4 PALADIN STUDY WITH ILUVIEN® PUBLISHED IN
PEER-REVIEWED
JOURNAL OPHTHALMOLOGY
* ALIMERA SCIENCES INC - ILUVIEN TREATMENT RESULTED IN A
70.5%
REDUCTION IN TREATMENT BURDEN
* ALIMERA SCIENCES INC - BEST CORRECTED VISUAL ACUITY AND
CENTRAL
SUBFIELD THICKNESS WERE SIGNIFICANTLY IMPROVED AT 36 MONTHS
* ALIMERA SCIENCES INC - RESULTS CONFIRM THAT USE OF PRIOR
CORTICOSTEROID PER U.S. LABEL MITIGATES RISK OF IOP LOWERING
SURGERY
Source text for Eikon: ID:nGNXcd1SpW
Further company coverage: ALIM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alimera Sciences
See all newsBrief: ANI Pharmaceuticals And Alimera Sciences Announce Closing Date Of Merger
Brief: Ani Pharmaceuticals Provides Update On Closing Of Acquisition Of Alimera Sciences
U.S. STOCKS ON THE MOVE-JPMorgan, automakers, energy firms
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Brief: Alimera Sciences Files Lawsuit To Compel ANI To Close Merger